Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02359019 · ClinicalTrials.gov registry record · Phase 2
MK-3475 as Maintenance Therapy in Extensive Stage SCLC
A Phase 2 study of Extensive Stage Small Cell Lung Carcinoma, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT02359019 is a Phase 2 study of Extensive Stage Small Cell Lung Carcinoma that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 45 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT02359019, a Phase 2 study of Extensive Stage Small Cell Lung Carcinoma, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial studies how well pembrolizumab works in treating patients with extensive stage small cell lung cancer after completion of combination chemotherapy. Pembrolizumab may be effective in controlling small cell lung cancer for a longer period of time in patients with responsive or stable disease after completion of combination chemotherapy.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
Study Locations (5)
Michigan
- University of Michigan - Ann Arbor
- Barbara Ann Karmanos Cancer Institute - Detroit
Illinois
- Rush University Medical Center - Chicago
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- Penn State Milton S. Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-02 |
| Est. Completion | 2018-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02359019
The ClinicalTrials.gov registry entry for NCT02359019 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Extensive Stage Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02359019 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Michigan, Illinois, Ohio.
Frequently Asked Questions
What is clinical trial NCT02359019 about?
NCT02359019 is a clinical study titled "MK-3475 as Maintenance Therapy in Extensive Stage SCLC". This phase II trial studies how well pembrolizumab works in treating patients with extensive stage small cell lung cancer after completion of combination chemotherapy. Pembrolizumab may be effective in controlling small cell lung cancer for a longer period of time in patients with responsive or stab...
What is the current status of trial NCT02359019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2015-02. Estimated completion is 2018-10.
What conditions does trial NCT02359019 study?
This clinical trial studies the following conditions: Extensive Stage Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT02359019?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02359019?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02359019 being conducted?
This trial has 5 study locations across Illinois, Michigan, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extensive Stage Small Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.